Lakefront Biotherapeutics NVLKFT
What Lakefront Biotherapeutics NV does.
We are a biotechnology company built to bring meaningful medicines to patients with serious diseases. We combine world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, we prioritize oncology and immunology & inflammation (“I&I”) programs with clear clinical proof-of-concept in emerging areas.
As of December 31, 2025, our clinical pipeline included 1) GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE; 2) GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in relapsed/refractory non-hodgkin lymphoma (“R/R NHL”), and 3) GLPG5301, a B-cell maturation antigen (“BCMA”) CAR-T product candidate decentralized manufactured, currently in Phase 1 in relapsed/refractory multiple myeloma (“R/R MM”). GLPG5101 and GLPG5301 are both cell therapy products, while GLPG3667 is a non-cell therapy product. In both our oncology and I&I portfolios, we had multiple product candidates in early research stages as of December 2025.
Our total net revenues amounted to €1,112.2 million for the year ended December 31, 2025, including the release in revenues of the remaining deferred income (contract liability) of €1,069.0 million related to the OLCA with Gilead. We refer to the notes 6 and 7 of our consolidated financial statements for more details on revenue breakdown and geographical information.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $478.1M | $234.4M | $241.2M | $239.7M | $275.6M | $1.1B |
| Net income | -$305.4M | -$103.2M | -$218.0M | $211.7M | $74.1M | $320.9M |
| Free cash flow | -$469.9M | -$558.0M | -$527.9M | -$424.7M | -$336.7M | -$271.2M |
More on LKFT.
- Lakefront Biotherapeutics NV summary
- Lakefront Biotherapeutics NV financial statements
- Lakefront Biotherapeutics NV key metrics
- Lakefront Biotherapeutics NV health scores and style box
- Lakefront Biotherapeutics NV earnings
- Lakefront Biotherapeutics NV dividends
- Lakefront Biotherapeutics NV valuation
- Lakefront Biotherapeutics NV ownership and insiders
- Lakefront Biotherapeutics NV peers
Figures from Lakefront Biotherapeutics NV's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.